A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB (R²) COMBINATION IN PATIENTS WITH HIGH‐RISK REFRACTORY/RELAPSED DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) - Bouabdallah, R.; Zemmour, C.; Schiano de Collela, J.; Slama, B.; Bladé, J.; Belmecheri, N.; Coso, D.; Montes de Oca, C.; Stoppa, A.; Aurran‐Schleinitz, T.; Cournier, S.; Ivanov, V.; et al.